var path='https://www.tickertech.net'; function heading(heading) { document.write('
'+heading+' |
'+ ''+ ' |
'); } function hiLite(imgDocID,imgObjName) { document.images[imgDocID].src = eval(imgObjName + ".src"); } function showStatus(toshow) { window.status = toshow; } function checkChoose() { if (document.choose.ticker.value == "") { alert("Please enter symbols before clicking the go button"); return false; } else return true; } function popJT(url,name){ var xwid = screen.width; xwid = xwid - 10; javaticker = window.open(url,name,'width='+xwid+',height=100,resizable=yes,scrollbars=no,toolbar=no,location=no,directories=no,status=yes,menubar=no'); javaticker.opener.name="opener"; //javaticker.moveTo(0,30); } var allow = 0; var ref = ""+location; if ((ref.indexOf("cryptocurrencieschannel.com") > 0) || (ref.indexOf("cefchannel.com") > 0) || (ref.indexOf("bdcinvestor.com") > 0) || (ref.indexOf("tickertech.com") > 0) || (ref.indexOf("xxxx:") > 0) || (ref.indexOf("javascript:") > 0) || (ref.indexOf("filseclab.com") > 0) || (ref.indexOf("msnscache.com") > 0) || (ref.indexOf("toolbar.google.com") > 0) || (ref.indexOf("etfchannel.com") > 0) || (ref.indexOf("marketnewsvideo.com") > 0) || (ref.indexOf("news.google.com") > 0) || (ref.indexOf("dividendchannel.com") > 0) || (ref.indexOf("www.google.com") > 0) || (ref.indexOf("energystockchannel.com") > 0) || (ref.indexOf("metalschannel.com") > 0) || (ref.indexOf("portfoliochannel.com") > 0) || (ref.indexOf("canadastockchannel.com") > 0) || (ref.indexOf("theonlineinvestor.com") > 0) || (ref.indexOf("investhelp.com") > 0) || (ref.indexOf("preferredstockchannel.com") > 0) || (ref.indexOf("stockoptionschannel.com") > 0) || (ref.indexOf("holdingschannel.com") > 0) || (ref.indexOf("tickertech.net") > 0) || (ref.indexOf("historicalstockprice.com") > 0) || (ref.indexOf("splithistory.com") > 0) || (ref.indexOf("stocksplithistory.com") > 0) || (ref.indexOf("google.c") > 0) || (ref.indexOf("208.71.46.190") > 0) || (ref.indexOf("search.yahoo") > 0) || (ref.indexOf("sharesoutstandinghistory.com") > 0) || (ref.indexOf("marketcaphistory.com") > 0) || (ref.indexOf("ytdreturn.com") > 0) || (ref.indexOf("averageannualreturn.com") > 0) || (ref.indexOf("redinews.com") > 0) || (ref.indexOf("technicalanalysischannel.com") > 0) || (ref.indexOf("stockdma.com") > 0) || (ref.indexOf("stockrsi.com") > 0) || (ref.indexOf("stockmacd.com") > 0) || (ref.indexOf("topdividends.com") > 0) || (ref.indexOf("monthlydividendpayingstocks.com") > 0) || (ref.indexOf("nextearningsdate.com") > 0) || (ref.indexOf("pastearnings.com") > 0) || (ref.indexOf("historicalperatio.com") > 0) || (ref.indexOf("historicalearnings.com") > 0) || (ref.indexOf("webcache.googleusercontent.com") > 0)) { allow = 1; } function ShowTTIPage() { if (allow) { document.write('\n'); } if (allow) { document.write('
\n'); } if (allow) { document.write('3/26 - 7:01 AM \; \; | \n'); } if (allow) { document.write('Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data | \n'); } if (allow) { document.write('
3/18 - 7:01 AM \; \; | \n'); } if (allow) { document.write('Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda | \n'); } if (allow) { document.write('
3/11 - 7:01 AM \; \; | \n'); } if (allow) { document.write('Late-Breaking Presentation at American Academy of Dermatology 2024 Annual Meeting Shows that JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-To-Severe Plaque Psoriasis Through One Year | \n'); } if (allow) { document.write('
3/6 - 4:06 PM \; \; | \n'); } if (allow) { document.write('Protagonist Therapeutics to Participate in Upcoming Investor Conferences | \n'); } if (allow) { document.write('
2/27 - 4:11 PM \; \; | \n'); } if (allow) { document.write('Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update | \n'); } if (allow) { document.write('
2/27 - 4:07 PM \; \; | \n'); } if (allow) { document.write('Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update | \n'); } if (allow) { document.write('
2/21 - 5:01 PM \; \; | \n'); } if (allow) { document.write('New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera | \n'); } if (allow) { document.write('
2/20 - 4:06 PM \; \; | \n'); } if (allow) { document.write('Protagonist Therapeutics Reports Granting of Inducement Awards | \n'); } if (allow) { document.write('
2/7 - 5:01 PM \; \; | \n'); } if (allow) { document.write('New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study | \n'); } if (allow) { document.write('
2/1 - 6:01 AM \; \; | \n'); } if (allow) { document.write('Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset | \n'); } if (allow) { document.write('
1/31 - 4:11 PM \; \; | \n'); } if (allow) { document.write('Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset | \n'); } if (allow) { document.write('
1/31 - 4:07 PM \; \; | \n'); } if (allow) { document.write('Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset | \n'); } if (allow) { document.write('
1/29 - 7:31 AM \; \; | \n'); } if (allow) { document.write('Protagonist Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024 | \n'); } if (allow) { document.write('
1/3 - 7:31 AM \; \; | \n'); } if (allow) { document.write('Protagonist Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference | \n'); } if (allow) { document.write('
\n'); } if (allow) { document.write(' |